HIGHLIGHTS OF PRESCRIBING INFORMATION RYBREVANT FASPRO™ (amivantamab . . . The recommended dosages of RYBREVANT FASPRO, administered every 3 weeks in combination with carboplatin and pemetrexed, based on baseline body weight are provided in Table 2 Administer RYBREVANT FASPRO until disease progression or unacceptable toxicity
RYBREVANT® (amivantamab-vmjw) RYBREVANT FASPRO ™ is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic) or cannot be removed by surgery, and has certain abnormal epidermal growth factor receptor (EGFR) gene (s):
Rybrevant Faspro - Drugs. com Rybrevant Faspro treats adults with metastatic or inoperable non-small cell lung cancer with specific EGFR gene abnormalities It is a subcutaneous injection used either with lazertinib, carboplatin and pemetrexed, or alone Learn about side effects, the mechanism of action, and dosing
Rybrevant Faspro (Amivantamab Hyaluronidase-Lpuj) - WebMD Find patient medical information for Rybrevant Faspro (Amivantamab Hyaluronidase-Lpuj) on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings
Rybrevant Faspro (amivantamab and hyaluronidase injection): Side . . . Rybrevant Faspro (amivantamab and hyaluronidase injection) may treat, side effects, dosage, drug interactions, warnings, patient labeling, reviews, and related medications including drug comparison and health resources
Your guide to starting FASPRO or RYBREVANT RYBREVANT FASPROTM or RYBREVANT® can be given as a first treatment or a second treatment, alone or in combination with other medicines, depending on the type of EGFR mutation in non–small cell lung cancer (NSCLC)